Atomoxetine in the Treatment of the Most Common Comorbid Disorders of Attention-Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder and Anxiety Disorders

1. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003; 2:104-113Search in Google Scholar

2. Hechtman L. Assessment and diagnosis of attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2000; 9:481-49810.1016/S1056-4993(18)30102-0Search in Google Scholar

3. Dell’Agnello G, Maschietto D, Pancotto A, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Escobar R, Zuddas A. Atomoxetine hydrochloride in the treatment of children and adolescents with attentiondeficit/ hyperactivity disorder and comorbid oppositional defiant disorder: Results from a placebo-controlled Italian study. Eur Neuropsychopharmacol. 2009; 19: 822-83410.1016/j.euroneuro.2009.07.008Search in Google Scholar

4. Pactl et al. Hyperkinetická porucha a poruchy chování. 1st ed. Praha: Grada Publishing.2007; 240s.Search in Google Scholar

5. Aosaki T, Graybiel AM, Kimura M. Effect of the nigrostriatal dopamine system on acquired neural responses in the striatum of behaving monkeys.Science. 1994; 265:412-41510.1126/science.8023166Search in Google Scholar

6. Goldman-Rakic PS. Working memory dysfunction in schizophrenia.J Neuropsychiatry Clin Neurosci. 1994;6:348-35710.1176/jnp.6.4.348Search in Google Scholar

7. Sawaguchi T, Matsumura M, Kubota K: Catecholaminergic effects on neuronal activity related to a delayed response task in monkey prefrontal cortex.J Neurophysiol.1990; 63:1385-140010.1152/jn.1990.63.6.1385Search in Google Scholar

8. Aston-Jones G, Bloom FE: Norepinephrine containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli.J Neuroscience.1981;1:887-90010.1523/JNEUROSCI.01-08-00887.1981Search in Google Scholar

9. MTA Cooperative Group.Arch Gen Psychiatry. 1999; 56: 1073-86Search in Google Scholar

10. Conley R, Gupta SK, Sathya G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form.Curr Med Res Opin. 2006; 22(10):1879-9210.1185/030079906X132613Search in Google Scholar

11. Volkow N. et al. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry. 1999; 156 (1):19-2610.1176/ajp.156.1.19Search in Google Scholar

12. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res. 1998; 94: 127-5210.1016/S0166-4328(97)00175-7Search in Google Scholar

13. Wigal S B. Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults, CNS Drugs. 2009; 23 (1): 21Search in Google Scholar

14. Greydanus DE, Pratt HD, Patel DR. Attention deficit hyperactivity disorderacross the lifespan: the child, adolescent, and adult. Dis Mon .2007; 53 (2): 70-13.10.1016/j.disamonth.2007.01.00117386306Search in Google Scholar

15. Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005; 90:26-9.10.1136/adc.2004.059386Search in Google Scholar

16. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology.2002; 27(5): 699-71.110.1016/S0893-133X(02)00346-9Search in Google Scholar

17. Gehlert DR, Schober DA, Gackenheimer SL. Comparison of (R)-[‘H]tomoxetine and (R/S)-[‘H]nisoxetine binding in rat brain. J Neurochem. 1995; 64 (6): 2792-800.10.1046/j.1471-4159.1995.64062792.x7760060Search in Google Scholar

18. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003; 26(10): 729-40.10.2165/00002018-200326100-0000612862507Search in Google Scholar

19. Spencer TJ, Kratochvil CJ, Sangal RB, et al. Effects of atomoxetine on growth in children with attentiondeficit/ hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol. 2007; 17(5): 689-700.10.1089/cap.2006.010017979588Search in Google Scholar

20. Sangal RB, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidat on sleep in children with ADHD. Sleep. 2006; 29(12): 1573-85.10.1093/sleep/29.12.157317252888Search in Google Scholar

21. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2003; 13: 53-63.10.1089/10445460332166619912804126Search in Google Scholar

22. Eli Lilly and Company. Atomoxetine (Strattera™) prescribing information [online]. Available from URL: http://pi.lilly.com/tis/strattera-pi.pdf [Accessed 2009 Feb 9].Search in Google Scholar

23. Sauer J.M., Ring B.J., Witcher J.W. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005; 44:571-590.10.2165/00003088-200544060-0000215910008Search in Google Scholar

24. Michelson D. et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007; 68:582-587.10.4088/JCP.v68n0414Search in Google Scholar

25. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee RF, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D.Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry.2002;159:1896-190110.1176/appi.ajp.159.11.189612411225Search in Google Scholar

26. Jensen PS, Hinshaw SP, Kraemer HC, Lenora N, Newcorn JH, Abikoff HB, March JS, Arnold LE, Cantwell DP, Conners CK, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Pelham WE, Severe JB, Swanson JM, Wells KC, Wigal T, Vitiello B. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001; 40:147-15810.1097/00004583-200102000-0000911211363Search in Google Scholar

27. Kuhne M, Schachar R, Tannock R. Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1197; 36:1715-172510.1097/00004583-199712000-000209401333Search in Google Scholar

28. Raine A, Venables PH, Williams M. Relationships between central and autonomic measures of arousal at age 15 years and criminality at age 24 years. Arch Gen Psychiatry. 1990;47:1003-7.10.1001/archpsyc.1990.018102300190032241502Search in Google Scholar

29. AACAP Official Action.. Practice parameters for the assessment and treatment of children and adolescents with conduct disorder. J Am Acad Child Adolesc Psychiatry. 1997:36:122-39.Search in Google Scholar

30. Lahey BB, Hart EL, Pliszka S, Applegate B, McBurnett K. Neurophysiological correlates of conduct disorder: a rationale and a review. J Clin Child Psychol. 1993;22:141-53.10.1207/s15374424jccp2202_2Search in Google Scholar

31. Masi G, Manfredi A, Milone A. Predictors of nonresponse to psychosocial treatment in children and adolescents with disruptive behavior disorders. J Child Adolesc Psychopharmacol. 2011; 21:51-55.10.1089/cap.2010.003921309697Search in Google Scholar

32. American Academy of Child & Adolescent Psychiatry (AACAP). Preventive effects of treatment of disruptive behavior disorder in middle childhood on substance use and delinquent behavior. Journal of the American Academy of Child and Adolescent Psychiatry. 2007; 46 (1): 33-39.10.1097/01.chi.0000246051.53297.5717195727Search in Google Scholar

33. Sondeijker FEPL, Ferdinand RF, Oldehinkel AJ, Veenstra R, De Winter AF, Ormel J, Verhulst FC. Classes of adolescentswith disruptive behaviors in a general population sample. Soc Psychiatry Psychiatr Epidemiol. 2005; 40:931-93810.1007/s00127-005-0970-616222441Search in Google Scholar

34. Burns GL, Walsh JA. The influence of ADHD-hyperactivity/ impulsivity symptoms on the development of oppositional defiant disorder symptoms in a 2-year longitudinal study. J Abnorm Child Psychol. 2002; 30:245-25610.1023/A:1015102812958Search in Google Scholar

35. Chen TJH, Blum K, Mathews D, Fisher L, Schnautz N, Braverman ER, Schoolfield J, Downs BW, Comings DE. Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of “super normal controls” in psychiatricgenetic research of complex behavioral disorders. Med Hypotheses. 2005;65:703-70710.1016/j.mehy.2005.04.03715964153Search in Google Scholar

36. Comings DE, Chen C, Wu S, Muhleman D. Association of the androgen receptor gene (AR) with ADHD and conduct disorder. Neuroreport. 1999; 10:1589-159210.1097/00001756-199905140-0003610380986Search in Google Scholar

37. Oosterlaan J, Scheres A, Sergeant JA.Which executive functioning deficits are associated with AD/HD, ODD/CD and comorbid AD/HD+ODD/CD? J Abnorm Child Psychol.2005; 33:69-8510.1007/s10802-005-0935-y15759592Search in Google Scholar

38. Baving L, Rellum T, Kaucht M, Schmidt MH.Children with oppositional-defiant disorder display deviant attentional processingindependent of ADHD symptoms. J Neural Transm.2006;113:685-6910.1007/s00702-005-0345-x16082512Search in Google Scholar

39. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M: Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry.2001;40:168-17910.1097/00004583-200102000-0001111211365Search in Google Scholar

40. Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L; Atomoxetine ADHD/ODD Study Group: Atomoxetine for the treatment of attentiondeficit/ hyperactivity disorder and oppositional defiant disorder. Pediatrics.2008; 121:314-2010.1542/peds.2006-188018245404Search in Google Scholar

41. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebocontrolled trial. Pediatrics.2004; 114(1):1-810.1542/peds.114.1.e115231966Search in Google Scholar

42. Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord. 2004; 8:45-5210.1177/10870547040080020215801334Search in Google Scholar

43. Newcorn J, Spencer TJ, Biederman J, Milton DR, Michelson D. Atomoxetine treatment in children and adolescents with attentiondeficit/ hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry.2005; 44:240-24810.1097/00004583-200503000-0000815725968Search in Google Scholar

44. Biederman J, Spencer TJ, Newcorn JH, Gao H, Milton DR, Feldman PD, Witte MM: Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: A meta-analysis of controlled clinical trial data. Psychopharmacology.2007; 190:31-4110.1007/s00213-006-0565-217093981Search in Google Scholar

45. Anderson et al. Arch Gen Psychiatry.1987; 44(1):69 -7610.1001/archpsyc.1987.018001300810102432848Search in Google Scholar

46. Jennifer SB, Mark RD . Examining Alternative Explanations of the Covariation of ADHD and Anxiety Symptoms in Children. A Community Study J Abnorm Child Psychol. 2008; 36:67-7910.1007/s10802-007-9160-117636434Search in Google Scholar

47. Pliszka SR. Effect of anxiety on cognition, behavior, and stimulant response in ADHD. Journal of American Academy of Child & Adolescent Psychiatry.1989; 28:882-88710.1097/00004583-198911000-000122808258Search in Google Scholar

48. Costin J, Vance A, Barnett R, O’Shea M, Luk E. Attention deficit hyperactivity disorder and comorbid anxiety: Practitioner problems in treatment planning. Child & Adolescent Mental Health, 2002; 7:16-2410.1111/1475-3588.00005Search in Google Scholar

49. Taylor E, Schachar R, Thorley G, Wieselberg HM, Everitt B, Rutter M. Which boys respond to stimulant medication? A controlled trial of MPH in boys with disruptive behavior. Psychol Med.1987;17:121-14310.1017/S0033291700013039Search in Google Scholar

50. Diamond IR, Tannock R, Achachar RJ. Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry. 1999; 38:402-40910.1097/00004583-199904000-0001210199111Search in Google Scholar

51. Kratochvil, Newcorn, Arnold L, Duesenberg, Emslie, Quintana, Sarkis, Wagner, GaoAO, Michelson, Biederman. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety aymptoms. J. Am. Acad. Child Adolesc. Psychiatry. 2005; 44(9): 915-24Search in Google Scholar

52. Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology. 2007; 194:197-20910.1007/s00213-007-0840-x17572882Search in Google Scholar

52. Geller, Donnelly, Lopez, Rubin, Newcorn, Sutton, Bakken, Packowski, Kelsey, Sumner. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J. Am. Acad. Child Adolesc Psychiatry. 2007;46(9): 111910.1097/chi.0b013e3180ca838517712235Search in Google Scholar

53. Milberger S, Biederman J, Faraone SV, Murphy J, Tsuang MT. Attention deficit hyperactivity disorder and comorbid disorders: Issues of overlapping symptoms. American Journal of Psychiatry.1995; 152: 1793-179910.1176/ajp.152.12.17938526248Search in Google Scholar